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FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) 
point mutations, are present in approximately one third of patients with acute myeloid 
leukemia (AML), and have been associated with an increased relapse rate. We have studied 
FLT3 mutations in paired presentation and relapse samples to ascertain the biology of these 
mutations and to evaluate whether they can be used as markers of minimal residual disease. 
Twenty four patients were wild type FLT3 at diagnosis and 4 acquired a FLT3 mutation at 
relapse (2 D835+, 2 ITD+), with a further patient acquiring an ITD at second relapse. Of 20 
patients positive at diagnosis (18 ITD+, 2 D835+), 5 who were all originally ITD+ had no 
detectable mutation at relapse, as determined by a sensitive radioactive polymerase chain 
reaction. One of these patients had acquired an N-Ras mutation not detectable at presentation. 
Furthermore, another patient had a completely different ITD at relapse which could not be 
detected in the presentation sample. These results indicate that FLT3 mutations are secondary 
events in leukemogenesis, are unstable and thus should be used cautiously for the detection of 
minimal residual disease.
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Approximately 80% of patients with acute myeloid leukemia (AML) below 55 years of age 
achieve complete remission (CR) following intensive induction therapy.
1 However, the 
actuarial survival at 5 years is only just over 40% because most patients relapse and die of 
their disease.
1 Considerable effort has therefore been directed at identifying molecular 
markers that can be used to detect residual disease or predict relapse at an earlier stage and 
lead to therapeutic intervention before overt hematological relapse occurs.
Ideally a candidate marker for minimal residual disease (MRD) should always or 
frequently be present in a specific disease, it should be easy to assay and stable, i.e. always 
present at relapse. In lymphoid malignancies, clonal rearrangements of either immunoglobulin 
or T-cell receptor genes are suitable for such analysis.
2 They occur in up to 90% of patients, 
can be detected using sensitive polymerase chain reaction (PCR) techniques, and reappear at 
relapse, although development of secondary rearrangements has been noted in some cases.
3
Studies evaluating their usefulness in clinical practice as a predictor of relapse have shown 
that the presence and level of residual leukemia can correlate with the risk of early relapse in 
acute lymphoid leukemia.
4 Similarly, the BCR/ABL fusion transcript is present in nearly all 
patients with chronic myeloid leukemia (CML), and a number of different approaches have 
been used to correlate this marker with disease status and outcome.
5-8 
In AML, the use of MRD has been limited by the lack of suitable specific molecular 
markers and the diversity of those that do exist. Although cytogenetic markers have proved to 
be significant prognostic indicators, less than 50% of patients have an identifiable cytogenetic 
abnormality.
1 Some patients have partial or complete loss or gain of a chromosome, but such 
abnormalities can only be identified using relatively insensitive "whole cell" techniques, and 
even the more sensitive fluorescence in situ hybridization technique requires evaluation of 
thousands of cells.
9 Three molecular markers that have been used for MRD studies are the 
PML/RAR￿ fusion transcript arising from the t(15;17) translocation, AML1/ETO arising 
from t(8;21) and CBFB/MYH11 from inv(16).
10-13 Quantitative assays are necessary, 
particularly as several groups have shown that patients who are positive for AML1/ETO using 
sensitive reverse transcription (RT)-PCR assays can remain in morphological and clinical 
remission for many years.
14,15 Nevertheless, re-appearance of the marker, or persistence at a 
certain level post-induction chemotherapy, does generally signify an increased risk of 
relapse.
16,17
However, these 3 markers together only account for approximately one quarter of 
adult AML patients,
1 and other markers are required to extend the potential application of 
MRD to more AML patients. Recent studies have demonstrated that mutations in the FLT3 
gene occur in about one third of adult AML patients. In 22% - 27% of patients there is an 
internal tandem duplication (ITD) in the juxtamembrane region between exons 14 and 15
18,19 
(previously called exons 11 and 12).
20 The extra sequence varies between 18 base pairs (bps) 
and 222bps (as detected in one patient in the present study) but the resulting protein sequence 
remains in frame and is thought to lead to a constitutively activated  tyrosine kinase 
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21-23 Multivariate analysis has shown that presence of the mutation is the most 
significant factor predicting for relapse, and it can add additional prognostic information to 
cytogenetic risk group.
19 A further 7% of patients have a mutation of aspartate residue 835 
(D835) in the activation loop of the second kinase domain, predominantly to tyrosine or 
valine, but occasionally to other amino acids.
24,25 This also leads to an activated receptor, 
although the clinical significance is unclear at present due to the small number of patients 
studied.
In order to gain further insight into the role of FLT3 mutations in AML and to 
determine whether they are suitable markers for MRD, we have therefore studied paired 
samples from patients at presentation and relapse for the presence of ITDs and D835 
alterations. 
Materials and Methods
Patients    Paired peripheral blood or bone marrow samples at presentation and first relapse 
were available from 44 patients with de novo AML who were treated with protocols from the 
United Kingdom Medical Research council (MRC) AML 10 and 12 trials.
1,19 A further 
sample at second relapse was obtained from one patient. Eleven of these patients had AML 
French American British type M1, 7 M2, 5 M3, 13 M4, 7 M5 and 1 patient had RAEB-t. 
Median age at presentation was 42 years (range 12 - 61 years), and median white cell count 
was 50.1 x 10
9/L (range 0.8 - 541 x 10
9/L). DNA samples were used for analysis in 42 
patients, in the remaining 2 patients only RNA samples were available. Paired DNA samples 
from patients at presentation and first complete remission (CR) following induction 
chemotherapy were also studied in 13 AML patients who all had a mutation in the FLT3 gene 
at diagnosis. CR was defined as a normocellular bone marrow containing less than 5% blast 
cells. Results of FLT3/ITD analysis at diagnosis have already been reported on some of the 
patients used in these studies.
19 
Detection of mutations in the FLT3 gene
ITDs    For FLT3/ITDs, genomic DNA was amplified as previously described to produce a 
fragment of 328bps from wild type (WT) alleles which included exons 14 and 15 and the 
intervening intron.
19 The same primers were used to analyse cDNA, but the fragment 
produced was 90bps smaller. Semi-quantitative PCR using a 
32P-labelled PCR primer was 
also carried out as previously described.
19 In order to evaluate sensitivity of the technique, 
wild type cells were mixed with cells from a patient carrying predominantly mutant alleles to 
create nine different mixtures containing between 100% and 0.01% patient cells. DNA was 
extracted and assayed radioactively. Reproducibility was assessed by 5 separate analyses of 3 
patient samples with high, intermediate or low level of mutant FLT3.
 D835    Mutations at residue D835 in exon 20, (previously exon 17) were detected as 
described by Yamamoto  et al.
24 Approximately 100ng DNA was added to a reaction mix 
containing 1 x buffer (16 mM (NH4)2SO4, 67 mM Tris HCl pH 8.8, 0.01% Tween 20), 1.0 
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The mixture was heated to 95
oC for 5 minutes and held at 85
oC whilst 1 µL containing 0.5U 
BIOTAQ DNA polymerase (Bioline, London, UK) was added; then 35 cycles each of 95
oC 
for 30 seconds, 63
oC for 30 seconds, and 72
oC for 30 seconds were performed, followed by 5 
minutes at 72
oC. Amplified products were digested with EcoRV then electrophoresed through 
4% agarose gels and visualized under UV light with ethidium bromide staining. In alleles 
containing a D835 mutation the 114bp PCR fragment remained uncut but in WT alleles it was 
digested to fragments of 68 and 46bps.
Polymorphic marker analysis    In cases where differences were observed between the results 
at presentation and relapse, 3 polymorphic markers were used to confirm that the DNA 
samples were from the same patient: KB9 on chromosome 19, D21S270 and D21S65 on 
chromosome 21.
26,27 One primer from each pair (Table 1) was 
32P end-labelled and PCR was 
performed as described above except that only 25 cycles of amplification were used and the 
annealing temperatures were 58
oC for D21S270 and D21S65, 65
oC for KB9. Products were 
electrophoresed through denaturing polyacrylamide gels (7M urea, 6% polyacrylamide 
crosslinker ratio 37.5:1, 0.5 x Tris-Borate-EDTA), the gels were dried and exposed to 
Hyperfilm (Amersham, Little Chalfont, UK).
Table 1. Oligonucleotide primer used in PCR analysis
Oligonucleotide primer
FLT3/ITD 
FLT3/ITD                                        
F
R
5'-GCAATTTAGGTATGAAAGCCAGC-3'
5'-CTTTCAGCATTTTGACGGCAACC-3'
FLT3/D835                                      
FLT3/D835                                      
F
R
5'-CCGCCAGGAACGTGCTTG-3'
5'-GCAGCCTCACATTGCCCC-3'
N-RAS exon 1 (DNA)                         F
R
5'-GACTGAGTACAAACTGGTGG-3'
5'-TGCATAACTGAATGTATACCC-3'
N-RAS exon 2 (DNA)                         F
R
5'-CAAGTGGTTATAGATGGTGAAACC-3'
5'-AAGATCATCCTTTCAGAGAAAATAAT-3'
N-RAS exons 1+2 (cDNA)                  F
R
5'-CTGTCCAAAGCAGAGGCAGTG-3'
5'-AGGCTTCCTCTGTGTATTTGCC-3'
KB9                                                  F
R
5'-TGCAAAGGCTTGGAGGGCTGATG-3'
5'-ATCTCGGACAACAGCAGGCCTCG-3'
D21S270                                          F
R
5'-GAAATGTTTTAATAAATGGTGGTTA-3'
5'-ACAAAGTTATGGTCAAGGGG-3'
D21S65                                            F
R
5'-CCGAAAACTTACTGGAGAAC-3'
5'-GATCATCCAGGAATCACCAA-3'
Cloning and sequencing of PCR products    PCR products from ITD+ patients were either 
sequenced directly or were cloned into the pGEM-T vector (Promega, Madison, WI) and 
selected clones sequenced using an Applied Biosystem 310 Analyzer with BigDye version 2 
terminator chemistry (Applied Biosystems, Foster City, CA).
Detection of N-Ras gene mutations   Samples were screened for mutations in codons 12, 13 
and 61 of the N-Ras gene using heteroduplex analysis (WAVE technology, Transgenomic 
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containing codons 12 and 13, and a 201bp fragment for exon 2 containing codon 61. Thirty 
five cycles of amplification were performed on approximately 100ng genomic DNA using 
0.625 units HotStarTaq™ (Qiagen, Ltd UK) per 25 µL reaction, 1 x manufacturer's buffer, 
200 µM dNTPs, and 12.5 pmol each primer (Table 1). After an initial denaturing cycle of 15 
minutes at 95
 oC, each cycle was 30 seconds at 94
oC, 60 seconds at 55.5
oC, one minute at 
72
oC, followed by 10 minutes at 72
 oC. PCR products were denatured at 95
 oC for 5 minutes 
then cooled slowly to 25
oC to allow heteroduplexes to form and analysed by denaturing high 
performance liquid chromatography (dHPLC). For cDNA a single fragment of 296bp was 
amplified which covered exons 1 and 2, and the annealing temperature was 64
oC. The 
sensitivity of the dHPLC is such that ￿10% mutant DNA can be confidently detected in a 
sample (manuscript in preparation). Samples exhibiting an abnormal dHPLC profile were 
sequenced as above. 
Results
Evaluation of semi-quantitative PCR analysis
Sensitivity of the method was determined from analysis of mixtures of wild type cells and 
cells from a patient with 94% FLT3/ITD alleles. The mutant could be detected when ￿0.5% 
of total FLT3. Quantification of the different mixtures gave results which were in good 
agreement with the expected values: expected 47% mutant, observed 48%; 19% and 23%; 
9.4% and 12.8%; 4.7% and 5%; 1% and 1.4% respectively. The results were highly 
reproducible: 5 analyses of 3 samples with different FLT3/ITD levels gave mean ± SD values 
of 94.4% ± 0.5% (range 93%-95%), 53.5% ± 1.1% (52%-55%) and 12.8% ± 0.8% (12-14%) 
respectively.
Paired presentation/remission samples
Remission samples from 13 patients who had a FLT3 mutation at presentation were studied. 
All 13 patients had an ITD, median mutant level 44% of total FLT3 (range 2% - 90%), and 1 
patient also had a D835 mutation (D835Y). In remission all patients lost their mutation(s) 
confirming that FLT3 mutations are leukemia-specific. 
Table 2.  FLT3 status and relative percentage of mutant in peripheral blood or bone 
marrow from 44 AML patients at presentation and relapse 
                       PRESENTATION                                    RELAPSE
Number FLT3 % Mutant Sample % Blasts FLT3 % Mutant Sample % Blasts
  1 WT PB MNC 90 WT NA 76
  2 WT BM 97 WT PB MNC NA
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  4 WT PB MNC 28 WT BM 42
  5 WT NA 100 WT BM 95
  6 WT NA 100 WT BM 60
  7 WT PB NA WT BM 85
  8 WT BM 98 WT PB 52
  9 WT PB 95 WT PB 80
10 WT BM 89 WT BM 96
11 WT PB 99 WT PB 99
12 WT PB 80 WT BM NA
13 WT BM 86 WT BM 60
14 WT BM 58 WT BM 90
15 WT BM 90 WT BM 87
16* WT BM 72 WT (ITD+) (45) BM (PB) 13 (87)
17 WT BM NA WT BM 11
18 WT PB 78 WT BM 56
19 WT BM 90 WT BM 64
20 WT BM 90 WT BM 74
21 WT PB MNC 90 D835+ ￿50 PB MNC NA
22 WT BM 87 D835+ ￿50 BM NA
23 WT PB MNC 90 ITD+ 42 BM 95
24 WT BM 95 ITD+ 38 BM 95
25 ITD+ 20 PB MNC 53 WT BM 55
26 ITD+ 6 BM 88 WT BM 92
27 ITD+ 11 PB 80 WT BM 82
28 ITD+ 28 BM 94 WT BM 85
29 ITD+ 44 BM 95 WT BM 44
30 D835+ ￿50 BM 95 D835+ ￿50 BM 96
31 D835+ ￿50 BM 60 D835+ ￿50 BM 60
32 ITD+ 13 BM 55 ITD+ 16 BM 96
33 ITD+ 39 BM 51 ITD+ 39 BM 60
34 ITD+ 44 PB MNC 77 ITD+ 45 NA NA
35 ITD+ 82 BM 97 ITD+ 84 BM 92
36 ITD+ 86 BM 86 ITD+ 83 PB 93
37 ITD+ 91 PB 70 ITD+ 91 BM NA
38 ITD+ 5 BM NA ITD+ 35 PB 97
39 ITD+ 23 PB MNC 86 ITD+ 88 BM 100
40 ITD+ 25 PB 79 ITD+ 50 PB 99
41 ITD+ 26+2 BM 90 ITD+ 56+14 BM 94
42 ITD+ 28 +3+1 BM 80 ITD+ 41 BM 99
43 ITD+ 40 PB MNC 88 ITD+ 69 PB MNC NA
44** ITD+ 44 BM 89 ITD+ 60 PB NA
MNC indicates mononuclear cells; BM, bone marrow; PB, peripheral blood; NA, not available
* Information in brackets relates to second relapse
** Different mutations were detected at presentation and relapse
Paired presentation/relapse samples
Patients without a FLT3 mutation at presentation    Of the 24 patients studied who had only 
WT FLT3 alleles at presentation, 20 patients remained WT at first relapse and 4 patients had 
acquired a FLT3 mutation (Table 2). Two patients acquired a D835 mutation, both G -> T 
leading to substitution of tyrosine for aspartate, and 2 patients gained a FLT3/ITD. The D835 
mutants accounted for approximately half of the total FLT3 in the samples, and in the patients 
with ITDs the mutant levels were 38% and 42% respectively, suggesting that the majority of 
cells at relapse were heterozygous for the mutant alleles. No ITD was detected in presentation 
samples from the latter 2 patients using the more sensitive radioactive PCR and all 4 patients 
had high blast counts at diagnosis (patients 21-24, Table 2). These results suggested that a 
FLT3 mutation had not been missed at diagnosis and that its acquisition at relapse was 
evidence of clonal progression. In 3 of these 4 patients, sufficient DNA was available at both
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sequences. In each case they confirmed that the 2 samples came from the same individual. 
The median time between  remission and relapse was similar in the patients who remained 
WT and those who acquired a FLT3 mutation (367 days, range 70 - 1779). One patient who 
had only WT FLT3 alleles at presentation and first relapse acquired a FLT3/ITD at second 
relapse with a mutant level of 45%. Polymorphic markers indicated that all 3 samples were 
from the same patient. 
Patients with a FLT3 mutation at presentation    Twenty patients were studied who had a 
FLT3 mutation at presentation, 18 were ITD+ with median mutant level 28% (range 5% -
91%) and 2 had D835Y mutations at about the 50% mutant level (Table 2). The median time 
to relapse was 218 days, range 38 - 716, which was less than in those patients who had not 
had a FLT3 mutation at presentation (P = .008, Student's t-test). 
Five patients (25%) lost their FLT3 mutation at relapse. All had presented with an ITD 
and the mutant levels were 6%, 11%, 20%, 28% and 44% respectively. Polymorphism 
analysis demonstrated that the paired samples were from the same individual in 4 cases from 
whom DNA samples were available (Figure 1); only RNA was available in the remaining 
patient. The loss was confirmed by radioactive PCR. In 4 of the 5 patients, the percentage of 
blast cells was similar in the presentation and relapse samples (#25-28, Table 2) and therefore 
it is unlikely that the mutation had been missed at relapse. In the remaining patient (#29), the 
blast cell count was lower at relapse (44%) than at presentation (95%). However, at diagnosis 
all cells appeared to be heterozygous for the mutation (mutant level 44%), and therefore, even 
with the lower blast cell count, a heterozygous mutation would still have been well within the 
limits of detection of the technique. 
Figure 1  Polymorphic marker analysis in 2 AML patients at presentation (P) and 
relapse (R). Both patients presented with a FLT3/ITD which was lost at relapse.
Fifteen patients had a FLT3 mutation at both presentation and relapse. Two had 
D835Y mutations at both stages of their disease and 13 had ITDs. Sequencing and semi-
quantitative PCR showed that 6 patients relapsed with the same ITD at approximately the 
same level (#32-37, Table 2). The median difference between presentation and relapse in the 
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which were consistent with homozygosity or hemizygosity in most blast cells at both 
presentation and relapse (#35-37). Six patients relapsed with the same ITD but at an increased 
level, where the median difference between presentation and relapse in the level of mutant 
was 29.5% (range 13.5% to 45%) (# 38-43, Table 2). In 1 of these patients, 3 different ITDs 
were detected at diagnosis (mutant levels 28%, 3%, 1% respectively), but only the 
predominant mutation was present at relapse (#42, Table 2). Another patient (#41, Table 2) 
had 2 different ITDs at diagnosis, mutant levels 26% and 2%, and both were increased at 
relapse, 56% and 14% respectively. The remaining patient who was ITD+ at presentation, 
mutant level 44%, relapsed with a different ITD, mutant level 60% (#44, Table 2). The 
relapse mutation was not detectable in the presentation sample using radioactive PCR 
analysis. At presentation the ITD was 33bps, nucleotides 36503 - 36535 from the DNA 
sequence (Genbank accession number 13628652) whereas at relapse the ITD was 60 bps, 51 
bps from nucleotides 36481 - 36531 plus an additional insertion of 9 bps (Figure 2). 
Polymorphic markers confirmed that the samples were from the same individual.
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Figure 2  Diagram to show the position of the FLT3/ITDs detected in one patient at 
presentation and relapse.
Analysis of N-Ras mutations in selected patients
Recent studies indicated that the presence of both a FLT3 and an N-Ras mutation in the same 
individual is infrequent,
18 suggesting that both mutations confer a proliferative or survival 
advantage through a common pathway. We therefore determined N-Ras mutational status at 
codons 12, 13 and 61 both at presentation and at relapse in those patients whose FLT3 status 
had changed. Of the 4 patients who acquired a FLT3 mutation at first relapse, none had had 
an N-Ras mutation at presentation and one acquired an N-Ras codon 61 (position 2, A -> G) 
mutation at relapse, co-incident with the development of a D835Y mutation. Of the 5 patients 
who lost an ITD at relapse, only 1 had acquired an N-Ras mutation in codon 12 (position 2, 
G-> A).
Discussion
In hematological malignancies with disease specific markers, the ability to test for MRD 
using sensitive molecular analyses is now a useful tool for predicting which patients are at 
risk for relapse. This information is also used in determining therapeutic strategies. For 
example, in patients post allogeneic transplantation for CML, intervention with donor 
lymphocyte infusions before the onset of hematologic relapse has been shown to be 
associated with an increased likelihood of anti-leukemic response and absence of bone 
marrow aplasia.
28 Similarly, in acute promyelocytic leukemia, conversion to PCR positivity 
for PML/RAR￿ in 2 successive bone marrow samples post-consolidation chemother apy is 
being used as a trigger to initiate salvage treatment.
16 However, the clinical potential for such 
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activating mutations in the FLT3 gene as the most common mutation in AML, occurring in up 
to one third of adult patients,
18,19,24 suggests that the mutations may be a relevant marker for 
MRD. 
In order to investigate this we first confirmed that the mutation is only found in 
leukemic cells. Analysis of a small group of 13 patients in morphological remission 
demonstrated that neither the presentation ITDs nor D835 mutation could be detected in bone 
marrow or peripheral blood samples obtained after induction chemotherapy. Eight of the 
patients had had mutant levels of 40% - 46% of total FLT3, indicating that the majority of 
cells carried the mutation (assuming heterozygosity), and 2 of the patients had had evidence 
for biallelic mutations or loss of one allele, with mutant levels of 74% and 90% respectively. 
For a leukemic marker to be clinically useful as an early predictor of relapse, it is 
important that the marker consistently reappears at relapse. However, 5 of the 20 patients 
(25%) who were positive for a FLT3 mutation at diagnosis lost their mutation at relapse. All 
had had ITDs and the level of mutant suggests that in 3 of them at least half of the cells in the 
sample analyzed carried the mutation. This is consistent with a study by Nakano et al
29 in 
which 1 out of 6 ITD+ patients at presentation were FLT3/WT at relapse, but differs from 
Schnittger et al
30 who reported that all 25 patients with a mutation at presentation relapsed 
with the same marker. The inability to detect a mutation at relapse in our study cannot be 
attributed to insensitivity of the technique used, as in all 5 cases the negative results from the 
cold PCR used bone marrow samples and were confirmed by the more sensitive radioactive 
PCR which can detect ITDs at least at the 0.5% level. Furthermore, in 4 of the 5 patients the 
blast cell counts were similar to those at presentation.A number of other complexities arise 
that are relevant for MRD detection, particularly for ITDs. Two patients had evidence of more 
than 1 mutation at diagnosis and in 1 of these patients only 1 of the 3 ITDs was detected at 
relapse. This indicated that the different mutants were present in separate subclones, only 1 of 
which survived or was selected after chemotherapy. In the other patient both mutants were 
detected at relapse at increased levels, though in different relative proportions, and it is not 
possible to determine whether the mutants were in separate clones which both survived, or 
whether the minor mutant was acquired on the other allele in a cell which was already 
heterozygous for an ITD and neither clone was completely eliminated by the treatment. In 
addition, 1 patient with an ITD at diagnosis relapsed with a completely different ITD, which 
would present as a false negative result if mutation sequence-specific primers were utilized to 
improve the sensitivity of the assays used. Analysis of FLT3 mutations as an early indicator 
of relapse should therefore be used with caution.
The results of this study also shed light on the role of FLT3 mutations in the 
pathogenesis of AML. The findings show that these mutations may be present in only a 
minority of blast cells at presentation, and at relapse the ratio of mutant to WT allele 
frequently increases, as seen in 6 out of 12 patients with the same ITD mutation at 
presentation and relapse (#38-43, Table 2). Results in 3 of these patients were consistent with 
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appeared to be associated with the development of homozoygosity or hemizygosity for the 
mutant in at least some of the cells. This indicates that the FLT3 alterations can be secondary 
mutations arising in an already malignant clone, with selection of the subclone containing the 
FLT3 mutation because of the growth or survival advantage it confers. Five out of 24 patients 
(21%) who were WT at presentation acquired FLT3 mutations for the first time in either first 
or second relapse, which is similar to the frequency found at presentation.
18,19 This is fully in 
accord with the fact that FLT3 mutations are secondary events. It also indicates that the FLT3 
pathway is active in myeloid cells at the stage of differentiation equivalent to the clonogenic 
leukemic cell, as the presence of these random mutations occurring in an already transformed 
clone lead to its further selection. The observation that at relapse 1 out of 20 patients had a 
different mutation and 5 had lost the FLT3 mutation is also compatible with this model. For 
this to occur, another subclone would need to develop from a leukemic cell that had been 
present at diagnosis but did not contain the FLT3 mutation. To outgrow the mutant FLT3+ 
cells, this subclone must have acquired alternative mutation(s) imparting a greater 
survival/growth advantage than that provided by the original FLT3 mutation.  One possibility 
is a secondary mutation in N-Ras as such mutations have been documented to arise in relapse 
when not present at diagnosis.
31,29 This is a potential target as FLT3 activates N-Ras,
32 and the 
rarity of FLT3 mutations and N-Ras mutations in the same blast cells suggests that both 
mutations are predominantly using the same pathways.
18 In the 5 patients whom we studied 
who lost FLT3 mutations at relapse, only one, however, acquired an N-Ras mutation. 
Consequently, in future it may be informative to screen for mutations in other candidate 
genes. 
These results have implications for the therapeutic use of FLT3 kinase inhibitors in 
patients whose cells express FLT3 mutations.
33,34,35 As these mutations are secondary events, 
which is in marked contrast to the BCR/ABL translocation in CML, there will always be a 
high probability that leukemic subclones not containing the mutant will be present which will 
have a selection advantage in the presence of a FLT3 kinase inhibitor. Such inhibitors will, 
therefore need to be used in combination with other agents.
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